Celularity (CELU) EBT Margin Growth (1y) (2021 - 2025)
Celularity (CELU) EBT Margin Growth (1y) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -153.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -571.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 546.00 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4,709.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1,076.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1,911.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2,507.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 29,565.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -392.00 |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | 133,858.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 133,858.00 |
| Sep 30, 2025 | -26,354.00 |
| Jun 30, 2025 | -37,397.00 |
| Mar 31, 2025 | -2,294.00 |
| Dec 31, 2024 | -201,103.00 |
| Sep 30, 2024 | 230,639.00 |
| Jun 30, 2024 | 157,846.00 |
| Mar 31, 2024 | 147,692.00 |
| Dec 31, 2023 | -51,318.00 |
| Sep 30, 2023 | -259,520.00 |
| Jun 30, 2023 | -289,906.00 |
| Mar 31, 2023 | -56,760.00 |
| Dec 31, 2022 | 67,486.00 |
| Sep 30, 2022 | -35,449.00 |
| Jun 30, 2022 | 328,383.00 |
| Mar 31, 2022 | 200,612.00 |
| Dec 31, 2021 | -20,122.00 |
| Sep 30, 2021 | 185,047.00 |